Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin and GLP-1 receptor blockade during intraduodenal fat infusion in adults with type 2 diabetes
ACTRN12614001117606Phase 4Recruiting
- Sponsor
- The Little Group
- Start
- Apr 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of vildagliptin and exendin 9-39 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by The Little Group. Primary endpoints: Plasma triglyceride concentrations, Energy expenditure and 1 more. Started Apr 2016; status: recruiting.
02
Drugs
vildagliptinexendin 9-39
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12614001117606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001117606.